No approved hantavirus vaccine exists, and all candidates remain in early preclinical or initial Phase 1 stages as of October 2026, driving the 97.5% market-implied odds against approval this year. mRNA constructs, such as those tested in hamster models by UTMB researchers, showed single-dose protection against Andes virus in June 2026 publications, while collaborations like Moderna with Korea University and separate DNA vaccine efforts have advanced only to mouse or small human immunogenicity studies. Significant barriers include the need for multi-strain coverage, GMP manufacturing scale-up, large efficacy trials hindered by the virus’s sporadic rodent-borne transmission and low case numbers, and standard regulatory timelines that typically span years without emergency acceleration. A major outbreak could prompt faster funding and review, yet current surveillance data and development status indicate no realistic path to licensure before year-end.